دورية أكاديمية
أعرض في EDS

An Institutional Experience of a Tertiary Referral Center in Surgically Managing Patients With Gorlin Syndrome.

التفاصيل البيبلوغرافية
العنوان: An Institutional Experience of a Tertiary Referral Center in Surgically Managing Patients With Gorlin Syndrome.
المؤلفون: Dany M; Division of Dermatologic Surgery, Deprtment of Dermatology, Virginia Commonwealth University, Richmond, Virginia., Walker J; Division of Dermatologic Surgery, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania., Miller CJ; Division of Dermatologic Surgery, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania., Giordano CN; Division of Dermatologic Surgery, Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania.
المصدر: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] [Dermatol Surg] 2023 Dec 01; Vol. 49 (12), pp. 1077-1084. Date of Electronic Publication: 2023 Oct 24.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 9504371 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4725 (Electronic) Linking ISSN: 10760512 NLM ISO Abbreviation: Dermatol Surg Subsets: MEDLINE
أسماء مطبوعة: Publication: 2021- : [Philadelphia] : Wolters Kluwer Health
Original Publication: New York, NY : Elsevier Science, c1995-
مواضيع طبية MeSH: Basal Cell Nevus Syndrome*/surgery , Basal Cell Nevus Syndrome*/pathology , Surgeons* , Carcinoma, Basal Cell*/surgery , Carcinoma, Basal Cell*/pathology , Skin Neoplasms*/surgery , Skin Neoplasms*/pathology, Humans ; Quality of Life ; Tertiary Care Centers ; Mohs Surgery
مستخلص: Background: The lifetime risk for basal carcinoma (BCC) is 90% in patients with Gorlin syndrome, also known as basal cell nevus syndrome. Compared with non-Gorlin patients, Gorlin patients often develop BCCs at a younger age and in greater numbers up to 500 BCCs in a lifetime.
Objective: To review the options available for Gorlin patients and highlight existing knowledge gaps where future studies are indicated to optimize the care of this unique population.
Methods: We review the current literature on managing patients with Gorlin syndrome from the lens of a dermatologic surgeon.
Results: Although Mohs surgery is still the gold standard for large and aggressive BCCs, other less-invasive approaches may be considered for smaller, more numerous lesions. As dermatologic surgeons, we must be open to the full spectrum of surgical and nonsurgical options to individualize treatment and optimize patients' quality of life. Without maintaining a balance between optimal cure rate and volume management, Gorlin patients become at risk for surgical burn out and loss to follow-up.
Conclusion: Gorlin patients undergo numerous surgeries especially on the central face which can lead to disfigurement and reduce the quality of life. Identifying gaps in the current literature, continuing ongoing research, and eventually establishing appropriate guidelines that help to guide the formation of an individualized treatment plan is crucial in developing a balance between conservative and complex treatments for this population.
(Copyright © 2023 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.)
References: Thalakoti S, Geller T. Basal cell nevus syndrome or Gorlin syndrome. Handbook of Clinical Neurology (Vol 132). Elsevier B.V.; 2015; pp. 119–28.
Lang BM, Balermpas P, Bauer A, Blum A, et al. S2k guidelines for cutaneous basal cell carcinoma—Part 1: epidemiology, genetics and diagnosis. J Ger Soc Dermatol 2019;17:94–103.
Garg S, Dahiya N, Gupta S. Surgical scar revision: an overview. J Cutan Aesthet Surg 2014;7:3–13.
Shah M, Mavers M, Bree A, Fosko S, et al. Quality of life and depression assessment in nevoid basal cell carcinoma syndrome. Int J Dermatol 2011;50:268–76.
Lam C, Ou JC, Billingsley EM. “PTCH”-ing it together: a basal cell nevus syndrome review. Dermatol Surg. 2013;39:1557–72.
Palacios-Álvarez I, González-Sarmiento R, Fernández-López E. Gorlin syndrome. Actas Dermo-sifiliogr. 2018;109:207–17.
Pino LCdM, Balassiano LKdA, Sessim M, de Almeida APM, et al. Basal cell nevus syndrome: clinical and molecular review and case report. Int J Dermatol 2016;55:367–75.
Shevchenko A, Durkin JR, Moon AT. Generalized basaloid follicular hamartoma syndrome versus Gorlin syndrome: a diagnostic challenge. Pediatr Dermatol 2018;35:e396–e397.
Requena L, Fariña MC, Robledo M, Sangueza OP, et al. Multiple hereditary infundibulocystic basal cell carcinomas. A genodermatosis different from nevoid basal cell carcinoma syndrome. Arch Dermatol 1999;135:1227–35.
Ad Hoc Task Force, Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of dermatology, American College of Mohs surgery, American Society for dermatologic surgery association, and the American Society for Mohs surgery. J Am Acad Dermatol 2012;67:531–50.
Thomas DJ, King AR, Peat BG. Excision margins for nonmelanotic skin cancer. Plast Reconstr Surg 2003;112:57–63.
Kyrgidis A, Tzellos TG, Vahtsevanos K, Triaridis S. New concepts for basal cell carcinoma. Demographic, clinical, histological risk factors, and biomarkers. A systematic review of evidence regarding risk for tumor development, susceptibility for second primary and recurrence. J Surg Res 2010;159:545–56.
Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med 2015;88:167–79.
Hasan A, Akintola D. An update of Gorlin-Goltz syndrome. Prim Dental J 2018;7:38–41.
Mohs FE, Jones DL, Koranda FC. Microscopically controlled surgery for carcinomas in patients with nevoid basal cell carcinoma syndrome. Arch Dermatol 1980;116:777–9.
Tsuji T, Otake N, Nishimura M. Cryosurgery and topical fluorouracil: a treatment method for widespread basal cell epithelioma in basal cell nevus syndrome. J Dermatol 1993;20:507–13.
Sheridan AT, Dawber RPR. Curettage, electrosurgery and skin cancer. Australas J Dermatol 2000;41:19–30.
Barlow JO, Zalla MJ, Kyle A, DiCaudo DJ, et al. Treatment of basal cell carcinoma with curettage alone. J Am Acad Dermatol 2006;54:1039–45.
Salasche SJ. Curettage and electrodesiccation in the treatment of midfacial basal cell epithelioma. J Am Acad Dermatol 1983;8:496–503.
Foley P, Freeman M, Menter A, Siller G, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol 2009;48:1236–45.
Mosterd K, Thissen MRTM, Nelemans P, Kelleners-Smeets NWJ, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol 2008;159:864–70.
Girard C, Debu A, Bessis D, Blatière V, et al. Treatment of Gorlin syndrome (nevoid basal cell carcinoma syndrome) with methylaminolevulinate photodynamic therapy in seven patients, including two children: interest of tumescent anesthesia for pain control in children. J Eur Acad Dermatol Venereol 2013;27:e171–e175.
Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, Livideanu C, et al. Topical methyl aminolevulinate photodynamic therapy for management of basal cell carcinomas in patients with basal cell nevus syndrome improves patient's satisfaction and reduces the need for surgical procedures. J Eur Acad Dermatol Venereol 2011;25:861–4.
Basset-Seguin N, Bissonnette R, Girard C, Haedersdal M, et al. Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. J Eur Acad Dermatol Venereol 2014;28:626–32.
Maytin EV, Kaw U, Ilyas M, Mack JA, et al. Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: a bilaterally controlled comparison study. Photodiagnosis Photodyn Ther 2018;22:7–13.
Epstein EH, Lear J, Saldanha G, Tang JY, et al. Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome. J Clin Oncol 2018;36:e21626.
Nouri K, Chang A, Trent JT, Jiménez GP. Ultrapulse CO 2 used for the successful treatment of basal cell carcinomas found in patients with basal cell nevus syndrome. Dermatol Surg 2002;28:287–90.
Ferrara F, Lacava R, Barisani A, Messori S, et al. Combined CO 2 laser and photodynamic therapy enhances the efficacy of treatment of basal cell carcinomas. J Ger Soc Dermatol 2019;17:1251–6.
Salavastru C, Tiplica GS, Fritz K. Laser treatment of basal cell carcinoma. Hautarzt 2018;69:10–6.
Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med 2011;43:72–8.
Ibrahimi OA, Sakamoto FH, Tannous Z, Anderson RR. 755 nm alexandrite laser for the reduction of tumor burden in basal cell Nevus syndrome. Lasers Surg Med 2011;43:68–71.
Silverman MK, Kopf AW, Gladstein AH, Bart RS, et al. Recurrence rates of treated basal cell carcinomas: Part 4: X‐ray therapy. J Dermatol Surg Oncol 1992;18:549–54.
Rowe DE, Carroll RJ, Day CL. Long‐term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow‐up. J Dermatol Surg Oncol 1989;15:315–28.
Gailani M, Institute AB-J of the NC, 1997. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. academic.oup.com . https://academic.oup.com/jnci/article-abstract/89/15/1103/2526289.
Wilder RB, Shimm DS, Kittelson JM, Rogoff EE, et al. Recurrent basal cell carcinoma treated with radiation therapy. Arch Dermatol 1991;127:1668–72.
Karagas MR, McDonald JA, Greenberg ER, Stukel TA, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For the Skin Cancer Prevention Study Group. J Natl Cancer Inst 1996;88:1848–53.
Sterry W, Ruzicka T, Herrera E, Takwale A, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002;147:1227–36.
Vereecken P, Monsieur E, Petein M, Heenen M. Topical application of imiquimod for the treatment of high-risk facial basal cell carcinoma in Gorlin syndrome. J Dermatolog Treat 2004;15:120–1.
Eggert S, Claas U, Axel H, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod - PubMed. Eur J Dermatol 2002;12:569–72.
Ferreres JR, Macaya A, Jucglà A, Muniesa C, et al. Hundreds of basal cell carcinomas in a Gorlin-Goltz syndrome patient cured with imiquimod 5% cream. J Eur Acad Dermatol Venereol 2006;20:877–8.
Gross K, Kircik L, Kricorian G. 5% 5-Fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatol Surg 2007;33:433–9.
Strange PR, Lang PG. Long-term management of basal cell nevus syndrome with topical tretinoin and 5-fluorouracil. J Am Acad Dermatol 1992;27:842–5.
Tang JY, Chiou AS, Mackay-Wiggan JM, Aszterbaum M, et al. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. Cancer Prev Res 2014;7:292–9.
Martinez JC, Otley CC. Megasession: excision of numerous skin cancers in a single session. Dermatol Surg 2005;31:757–61.
Van Der Geer S, Ostertag JU, Krekels GAM. Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome. J Eur Acad Dermatol Venereol 2009;23:308–13.
تواريخ الأحداث: Date Created: 20231101 Date Completed: 20231130 Latest Revision: 20231201
رمز التحديث: 20240628
DOI: 10.1097/DSS.0000000000003990
PMID: 37910540
قاعدة البيانات: MEDLINE
الوصف
تدمد:1524-4725
DOI:10.1097/DSS.0000000000003990